TCMHTI:基于Transformer的青附蠲痹汤治疗类风湿关节炎的中药-靶点相互作用预测模型

TCMHTI: a Transformer-based herb-target interaction prediction model for Qingfu Juanbi Decoction in rheumatoid arthritis

  • 摘要:
    目的 采用改进的Transformer 模型预测青附蠲痹汤(QFJBD)治疗类风湿关节炎(RA)的潜在靶点,探究QFJBD治疗RA的网络药理机制。
    方法 首先,构建基于Transformer改进的中药-靶点的相互作用预测模型(TCMHTI)。采用受试者工作特征曲线下面积(AUC)、精确率-召回率曲线(PRC)和准确率三项指标评价,将TCMHTI模型与基线模型进行性能比较。随后,基于预测靶点构建蛋白质-蛋白质相互作用(PPI)网络,并根据度值排名确定前9个节点为核心靶点,利用TCMHTI预测靶点与网络药理学方法鉴定的靶点分别进行基因本体论(GO)功能注释和京都基因与基因组百科全书(KEGG)通路富集分析,并将富集分析结果进行对比。最后,通过分子对接和文献查阅对TCMHTI预测的核心靶点进行验证。
    结果 TCMHTI模型的AUC值为0.883,PRC值为0.849,准确率为 0.818,预测出49个QFJBD治疗RA的潜在靶点并筛选出9个核心靶点:肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-6、IL-10、IL-17A、簇抗原分化簇40(CD40)、细胞毒性T淋巴细胞相关抗原-4(CTLA4)、IL-4及信号转导和转录激活因子-3(STAT3)。富集分析显示,TCMHTI模型预测出49个靶点,富集到更多与RA直接相关的通路;而经典网络药理学虽得到64个靶点,但富集的通路与RA关联性较弱。分子对接显示QFJBD中的活性分子与RA靶点有良好的结合能,而文献调研结果也显示了QFJBD可以通过9个核心靶点来治疗RA。
    结论 TCMHTI模型比网络药理学方法具有更高的准确性,表明QFJBD主要通过影响TNF-α、IL-1β、IL-6等靶点及多个信号通路来发挥对RA的治疗作用。本研究为传统中医药与精准医学相结合提供了一个新的框架,并为开发针对疾病的中医靶向疗法提供了可行的见解。

     

    Abstract:
    Objective To predict the potential targets of Qingfu Juanbi Decoction (青附蠲痹汤, QFJBD) in treating rheumatoid arthritis (RA) using an improved Transformer model and investigate the network pharmacological mechanisms underlying QFJBD’s therapeutic effects on RA.
    Methods First, a traditional Chinese medicine herb-target interaction (TCMHTI) model was constructed to predict herb-target interactions based on Transformer improvement. The performance of the TCMHTI model was evaluated against baseline models using three metrics: area under the receiver operating characteristic curve (AUC), precision-recall curve (PRC), and accuracy. Subsequently, a protein-protein interaction (PPI) network was built based on the predicted targets, with core targets identified as the top nine nodes ranked by degree values. Gene Ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the targets predicted by TCMHTI and the targets identified through network pharmacology method for comparison. Then, the results were compared. Finally, the core targets predicted by TCMHTI were validated through molecular docking and literature review.
    Results The TCMHTI model achieved an AUC of 0.883, PRC of 0.849, and accuracy of 0.818, predicting 49 potential targets for QFJBD in RA treatment. Nine core targets were identified: tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, IL-17A, cluster of differentiation 40 (CD40), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), IL-4, and signal transducer and activator of transcription 3 (STAT3). The enrichment analysis demonstrated that the TCMHTI model predicted 49 targets and enriched more pathways directly associated with RA, whereas classical network pharmacology identified 64 targets but enriched pathways showing weaker relevance to RA. Molecular docking demonstrated that the active molecules in QFJBD exhibit favorable binding energy with RA targets, while literature research further revealed that QFJBD can treat RA through 9 core targets.
    Conclusion The TCMHTI model demonstrated greater accuracy than traditional network pharmacology methods, suggesting QFJBD exerts therapeutic effects on RA by regulating targets like TNF-α, IL-1β, and IL-6, as well as multiple signaling pathways. This study provides a novel framework for bridging traditional herbal knowledge with precision medicine, offering actionable insights for developing targeted TCM therapies against diseases.

     

/

返回文章
返回